ESR1 and intrahepatic cholangiocarcinoma: Our study yielded a new hypothesis that some drug families including tyrosine kinase inhibitor, cannabinoid receptor inhibitor and estrogen receptor inhibitor, may be investigated as candidate drugs for ICC treatment.